HOME >> BIOLOGY >> NEWS
How long is a child a child?

With an innovative combination of a novel application of synchrotron imaging, high-resolution microtomography, and developmental analysis, the team reconstructed tooth growth and determined the age at death of a fossil juvenile from Jebel Irhoud, Morocco. This study represents the first non-destructive approach to characterize dental development with a high degree of precision, as synchrotron images reveal microscopic internal growth lines without damage to the specimen. The team found that the Moroccan fossil child showed an equivalent degree of tooth development to living human children at the same age. These findings and other evidence suggest that modern biological, behavioural, and cultural characteristics appeared relatively late in the past six million years of human evolution.

Modern human origins continues to be one of the most hotly debated topics among anthropologists, and there is little consensus about where and when the first members of our species, Homo sapiens, became fully modern. While fossil evidence tells a complex tale of mosaic change during the African Stone Age, almost nothing is known about changes in human life history, or the timing of development, reproductive scheduling, and lifespan. Tooth growth, and most importantly molar tooth eruption age, represents one of the most powerful clues to reconstruct growth processes in fossil humans. By using incremental growth lines in teeth, similar to annual rings in trees, developmental rate and time may be accurately established millions of years after death. Research during the past two decades has shown that early fossil humans (australopithecines and early Homo) possessed short growth periods, which were more similar to chimpanzees than to living humans. However, it unclear when, in and which group of fossil humans, the modern condition of a relatively long childhood arose.

In this study, tooth growth and eruption was examined in one of the earliest representatives of Ho
'"/>

Contact: Sandra Jacob
jacob@eva.mpg.de
49-341-355-0122
Max-Planck-Gesellschaft
13-Mar-2007


Page: 1 2

Related biology news :

1. Adult survivors of childhood leukemia exercise less, worsening high risk for obesity and illness
2. Gene identified for Crohns disease in children
3. Gene discovered for type 1 diabetes in children
4. Key to tackling malaria may lie in bed nets for adults and older children
5. Gene variant increases risk for alcoholism following childhood abuse
6. Cord blood may preserve insulin levels in children with type 1 diabetes
7. Researchers isolate new risk marker for overweight children
8. Study suggests other causes for childhood brain aneurysms
9. Study shows lizard moms dress their children for success
10. Lucky 13 as new gene discovery offers further hope for childhood blindness
11. Call of the child

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: How long child child

(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/11/2014)... Minn. , Dec. 10, 2014  Data ... physiologic monitoring, has released a new series of ... of preclinical toxicology researchers. M series, part of ... toxicologists collect the best possible physiologic data when ... Adding functional endpoints to toxicology studies has ...
(Date:12/10/2014)... 2014  Valencell, a leader in performance biometric data ... demand from its licensees for highly accurate, clinically validated ... solely coming from fitness and health sectors, but first ... wearable is only as useful as the biometric data ... driver in long-term mass consumer adoption of wearable products," ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
(Date:12/19/2014)... 2014 LayerBio is an MIT spin-off ... care. The National Eye Institute (NEI) at the National ... I SBIR grant to develop a drug-eluting intraocular lens ... common cause of vision loss in people over age ... to Dr. Ken Mandell, LayerBio’s Founder and CEO, "There ...
(Date:12/19/2014)... The empty capsules market is ... population and technological innovations in the empty capsules ... catalysing the growth of the empty capsules market. ... , Scope of Report , The report will ... entrants/smaller firms to gauge the pulse of the ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
Cached News: